Source author record

Ziang Xu

Ziang Xu appears in the imported research catalog. Authorship, coauthor and topic links are available while profile ownership is still unclaimed.

ResearcherUnclaimed source record

Catalog footprint

What is connected

2works
4topics
4close collaborators

Actions

Connect this record

Log in to claim

Research graph

See the researcher in context

Open full explorer

Inspect adjacent papers, topics, institutions and collaborators without losing the researcher page.

Building this map preview

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

2 published item(s)

preprint2022arXiv

Patch-level instance-group discrimination with pretext-invariant learning for colitis scoring

Inflammatory bowel disease (IBD), in particular ulcerative colitis (UC), is graded by endoscopists and this assessment is the basis for risk stratification and therapy monitoring. Presently, endoscopic characterisation is largely operator dependant leading to sometimes undesirable clinical outcomes for patients with IBD. We focus on the Mayo Endoscopic Scoring (MES) system which is widely used but requires the reliable identification of subtle changes in mucosal inflammation. Most existing deep learning classification methods cannot detect these fine-grained changes which make UC grading such a challenging task. In this work, we introduce a novel patch-level instance-group discrimination with pretext-invariant representation learning (PLD-PIRL) for self-supervised learning (SSL). Our experiments demonstrate both improved accuracy and robustness compared to the baseline supervised network and several state-of-the-art SSL methods. Compared to the baseline (ResNet50) supervised classification our proposed PLD-PIRL obtained an improvement of 4.75% on hold-out test data and 6.64% on unseen center test data for top-1 accuracy.

preprint2022arXiv

Uncovering the dynamic effects of DEX treatment on lung cancer by integrating bioinformatic inference and multiscale modeling of scRNA-seq and proteomics data

Motivation: Lung cancer is one of the leading causes for cancer-related death, with a five-year survival rate of 18%. It is a priority for us to understand the underlying mechanisms that affect the implementation and effectiveness of lung cancer therapeutics. In this study, we combine the power of Bioinformatics and Systems Biology to comprehensively uncover functional and signaling pathways of drug treatment using bioinformatics inference and multiscale modeling of both scRNA-seq data and proteomics data. The innovative and cross-disciplinary approach can be further applied to other computational studies in tumorigenesis and oncotherapy. Results: A time series of lung adenocarcinoma-derived A549 cells after DEX treatment were analysed. (1) We first discovered the differentially expressed genes in those lung cancer cells. Then through the interrogation of their regulatory network, we identified key hub genes including TGF-\b{eta}, MYC, and SMAD3 varied underlie DEX treatment. Further enrichment analysis revealed the TGF-\b{eta} signaling pathway as the top enriched term. Those genes involved in the TGF-\b{eta} pathway and their crosstalk with the ERBB pathway presented a strong survival prognosis in clinical lung cancer samples. (2) Based on biological validation and further curation, a multiscale model of tumor regulation centered on both TGF-\b{eta}-induced and ERBB-amplified signaling pathways was developed to characterize the dynamics effects of DEX therapy on lung cancer cells. Our simulation results were well matched to available data of SMAD2, FOXO3, TGF\b{eta}1, and TGF\b{eta}R1 over the time course. Moreover, we provided predictions of different doses to illustrate the trend and therapeutic potential of DEX treatment.